PharmaVoice 2026년 2월 12일 Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
PharmaVoice 2026년 1월 29일 Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
PharmaVoice 2026년 1월 14일 Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
PharmaVoice 2025년 11월 24일 Eli Lilly becomes first drugmaker to hit $1 trillion in market value #Eli Lilly #drugmaking peers